147 related articles for article (PubMed ID: 37602646)
1. Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.
Muñoz AJ; Ortega L; Gutiérrez A; Gallardo E; Rubio-Rodríguez D; Rubio-Terrés C; Morón B; García-Alfonso P; Soria JM
J Med Econ; 2023; 26(1):1145-1154. PubMed ID: 37602646
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
Yan X; Gu X; Xu Z; Lin H; Wu B
Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
Folkerts K; Broughton J; Sheikh U; Mckaig S
J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
[No Abstract] [Full Text] [Related]
9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.
Li A; Carlson JJ; Kuderer NM; Schaefer JK; Li S; Garcia DA; Khorana AA; Carrier M; Lyman GH
Cancer; 2020 Apr; 126(8):1736-1748. PubMed ID: 31999844
[TBL] [Abstract][Full Text] [Related]
11. New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting.
Du J; Wu B
Clin Drug Investig; 2020 Jul; 40(7):653-663. PubMed ID: 32445169
[TBL] [Abstract][Full Text] [Related]
12. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
14. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.
Yan X; Gu X; Zhou L; Lin H; Wu B
Clin Drug Investig; 2016 Dec; 36(12):1001-1010. PubMed ID: 27581246
[TBL] [Abstract][Full Text] [Related]
16. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
18. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.
Potere N; Di Nisio M; Porreca E; Wang TF; Tagalakis V; Shivakumar S; Delluc A; Mallick R; Wells PS; Carrier M
Thromb Res; 2023 Jun; 226():82-85. PubMed ID: 37121015
[TBL] [Abstract][Full Text] [Related]
19. Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System.
de Brito AFS; Brito NC; Tanaka SKT; Ferreira VL; Ferreira Júnior ABS; Riveros BS; Nita ME
Value Health Reg Issues; 2022 Sep; 31():111-118. PubMed ID: 35640463
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]